Pharmaceutical Technology Licensing: An Analysis in the Field of Cardiovascular Disease

[1]  Shinji Suzuki,et al.  The effect of patent family information in patent citation network analysis: a comparative case study in the drivetrain domain , 2015, Scientometrics.

[2]  Jean W. Tom,et al.  Optimizing Knowledge Creation at Bristol-Myers Squibb—a Case Study within Pharmaceutical Development , 2015, Journal of Pharmaceutical Innovation.

[3]  Yuanjia Hu,et al.  Dendritic-cell-based technology landscape: Insights from patents and citation networks , 2015, Human vaccines & immunotherapeutics.

[4]  A. Sangamwar,et al.  Clearing the Fog of Anticancer Patents from 1993–2013: Through an In-Depth Technology Landscape & Target Analysis from Pioneer Research Institutes and Universities Worldwide , 2014, PloS one.

[5]  Kim Bure,et al.  The global intellectual property landscape of induced pluripotent stem cell technologies , 2014, Nature Biotechnology.

[6]  A. Sangamwar,et al.  Anticancer patent landscape and technology assessment of Indian public-funded research institutes and organizations , 2014, Expert opinion on therapeutic patents.

[7]  Vetle I. Torvik,et al.  Disambiguation and co-authorship networks of the U.S. patent inventor database (1975–2010) , 2014 .

[8]  Yitao Wang,et al.  Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations , 2014, Expert opinion on therapeutic patents.

[9]  Minsung Kim,et al.  Entropy and Gravity Concepts as New Methodological Indexes to Investigate Technological Convergence: Patent Network-Based Approach , 2014, PloS one.

[10]  Ellen-Marie Forsberg,et al.  Assessments of emerging science and technologies: Mapping the landscape , 2014 .

[11]  Yi Sun,et al.  Target network differences between western drugs and Chinese herbal ingredients in treating cardiovascular disease , 2014, BMC Bioinformatics.

[12]  M. Pirmohamed,et al.  Cardiovascular Pharmacogenomics: Expectations and Practical Benefits , 2014, Clinical pharmacology and therapeutics.

[13]  T. Brenner,et al.  Embeddedness of regions in European knowledge networks: a comparative analysis of inter-regional R&D collaborations, co-patents and co-publications , 2013 .

[14]  A J Coyle,et al.  Building a New Biomedical Ecosystem: Pfizer's Centers for Therapeutic Innovation , 2013, Clinical pharmacology and therapeutics.

[15]  John Hudson,et al.  Into the valley of death: research to innovation. , 2013, Drug discovery today.

[16]  D. Judd,et al.  Open Innovation in Drug Discovery research comes of age. , 2013, Drug discovery today.

[17]  R. Rosenson,et al.  Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield , 2013, Current Atherosclerosis Reports.

[18]  C. Kennedy.  The importance of drug discovery for treatment of cardiovascular diseases. , 2013, Future medicinal chemistry.

[19]  W. Greenlee.  Interview: Drug discovery and development in the field of cardiovascular disease , 2013 .

[20]  P. Germann,et al.  How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective , 2013, Human Genomics.

[21]  C. Morel,et al.  Enabling Policy Planning and Innovation Management through Patent Information and Co-Authorship Network Analyses: A Study of Tuberculosis in Brazil , 2012, PloS one.

[22]  R. Knabb,et al.  The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review , 2012, Expert opinion on therapeutic patents.

[23]  C. Sheridan.  Correction: Corrigendum: Industry continues dabbling with open innovation models , 2012, Nature Biotechnology.

[24]  T. Lancet.  Lessons from Lipitor and the broken blockbuster drug model , 2011, The Lancet.

[25]  C. Sheridan.  Industry continues dabbling with open innovation models , 2011, Nature Biotechnology.

[26]  George A. Barnett,et al.  Globalization of technology: Network analysis of global patents and trademarks , 2011 .

[27]  José Luis Ortega,et al.  Collaboration patterns in patent networks and their relationship with the transfer of technology: the case study of the CSIC patents , 2011, Scientometrics.

[28]  Carl S. Guynes,et al.  E-Commerce/Network Security Considerations , 2011, BIOINFORMATICS 2011.

[29]  I Sam Saguy,et al.  Reinventing R&D in an open innovation ecosystem. , 2011, Journal of food science.

[30]  B. Munos,et al.  Can Open‐Source Drug R&D Repower Pharmaceutical Innovation? , 2010, Clinical pharmacology and therapeutics.

[31]  K I Kaitin,et al.  Deconstructing the Drug Development Process: The New Face of Innovation , 2010, Clinical pharmacology and therapeutics.

[32]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[33]  Susie Stephens,et al.  Is open innovation the way forward for big pharma? , 2010, Nature Reviews Drug Discovery.

[34]  A. Gabrielsen,et al.  The use of network analyses for elucidating mechanisms in cardiovascular disease. , 2010, Molecular bioSystems.

[35]  Patrice Talaga,et al.  Open innovation: share or die... , 2009, Drug discovery today.

[36]  Robert J. W. Tijssen,et al.  Internationalisation of pharmaceutical R&D: how globalised are Europe's largest multinational companies? , 2009, Technol. Anal. Strateg. Manag..

[37]  Jordi Mestres,et al.  A chemogenomic approach to drug discovery: focus on cardiovascular diseases. , 2009, Drug discovery today.

[38]  E. Topol.  Past the wall in cardiovascular R&D , 2009, Nature Reviews Drug Discovery.

[39]  Koichi Futagami,et al.  Dynamic Analysis of Innovation and International Transfer of Technology through Licensing , 2007 .

[40]  Thed N. van Leeuwen,et al.  Research cooperation within the bio-pharmaceutical industry: Network analyses of co-publications within and between firms , 2007, Scientometrics.

[41]  Colleen V. Chien,et al.  Managing innovation: university-industry partnerships and the licensing of the Harvard mouse , 2004, Nature Biotechnology.

[42]  Denny P Schafer.  In-licensing as a business model , 2002, Nature Biotechnology.

[43]  C. Freeman.  Economics of Industrial Innovation , 1975 .

[44]  Schumpeter Tamada,et al.  Analysis of cooperative research and development networks on Japanese patents , 2010, J. Informetrics.

[45]  L. Gallo.  Cardiovascular Disease , 1995, GWUMC Department of Biochemistry Annual Spring Symposia.